Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Usefulness of Serum Carcinoembryonic Antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study

Oscar Arrieta123*, Cynthia Villarreal-Garza1, Luis Martínez-Barrera4, Marcelino Morales1, Yuzmiren Dorantes-Gallareta2, Omar Peña-Curiel2, Susana Contreras-Reyes2, Eleazar Omar Macedo-Pérez1 and Jorge Alatorre-Alexander13

Author Affiliations

1 Department of Medical Oncology, National Cancer Institute, Mexico City, Mexico

2 Laboratory of Experimental Oncology, National Cancer Institute, Mexico City, Mexico

3 Universidad Nacional Autónoma de México, Mexico City, Mexico

4 Department of Thoracic Oncology, National Institute of Respiratory Diseases, Mexico City, Mexico

For all author emails, please log on.

BMC Cancer 2013, 13:254  doi:10.1186/1471-2407-13-254

Published: 22 May 2013

Abstract

Background

High serum carcinoembryonic antigen (CEA) levels are an independent prognostic factor for recurrence and survival in patients with non-small cell lung cancer (NSCLC). Its role as a predictive marker of treatment response has not been widely characterized.

Methods

180 patients with advanced NSCLC (stage IIIB or Stage IV), who had an elevated CEA serum level (>10 ng/ml) at baseline and who had no more than one previous chemotherapy regimen, were included. CEA levels were measured after two treatment cycles of platinum based chemotherapy (93%) or a tyrosine kinase inhibitor (7%). We assessed the change in serum CEA levels and the association with response measured by RECIST criteria.

Results

After two chemotherapy cycles, the patients who achieved an objective response (OR, 28.3%) had a reduction of CEA levels of 55.6% (95% CI 64.3-46.8) compared to its basal level, with an area under the ROC curve (AURC) of 0.945 (95% CI 0.91-0.99), and a sensitivity and specificity of 90.2 and 89.9%, respectively, for a CEA reduction of ≥14%. Patients that achieved a decrease in CEA levels ≥14% presented an overall response in 78% of cases, stable disease in 20.3% and progression in 1.7%, while patients that did not attain a reduction ≥14% had an overall response of 4.1%, stable disease of 63.6% and progression of 32.2% (p < 0.001). Patients with stable (49.4%) and progressive disease (22.2%) had an increase of CEA levels of 9.4% (95% CI 1.5-17.3) and 87.5% (95% CI 60.9-114) from baseline, respectively (p < 0.001). The AURC for progressive disease was 0.911 (95% CI 0.86-0.961), with sensitivity and specificity of 85 and 15%, respectively, for a CEA increase of ≥18%. PFS was longer in patients with a ≥14% reduction in CEA (8.7 vs. 5.1 months, p < 0.001). Reduction of CEA was not predictive of OS.

Conclusions

A CEA level reduction is a sensitive and specific marker of OR, as well as a sensitive indicator for progression to chemotherapy in patients with advanced NSCLC who had an elevated CEA at baseline and had received no more than one chemotherapy regimen. A 14% decrease in CEA levels is associated with a longer PFS.

Keywords:
Carcinoembryonic antigen; Non small-cell lung cancer; Tumor markers; Prognosis; Response prediction